Get those Sunglasses, Baby: B Cell Lymphoma and Vitamin D

I don’t know about you, but I love reading good news about cancer treatment – especially when it offers a cheap, painless solution. Solution may be too strong a word, so let’s say – encouraging sign. A new study was just released that looked at 374 patients who had been newly diagnosed with diffuse large B-cell lymphoma.

The researchers found 50 percent of the patients in the study deficient in vitamin D. Those patients with deficient vitamin D levels had a 1.5-fold greater risk of disease progression and a two-fold greater risk of dying -- versus patients with optimal vitamin D levels -- after accounting for other patient factors associated with worse outcomes.

What’s even better is that it is fairly easy to maintain vitamin D levels through inexpensive daily supplements or 15 minutes in the sun three times a week in the summer, so that levels can be stored in body fat. (I knew there was a good use for that extra ten pounds I’ve been holding onto!)

Currently, the recommended intakes of vitamin D by age group are 200 International Units per day (IU/d) for young adults, 400 IU/d for those aged 51 to 70 years, and 600 IU/d for those over age 70.

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap